PATHOQUEST
24.11.2021 13:02:07 CET | Business Wire | Press release
PathoQuest, a leading contract research organization (CRO) for the biosafety testing of biologics with Next-Generation Sequencing (NGS) technologies, today announced that it has obtained a Good Manufacturing Practices (GMP) certificate for its quality control testing activities at its French-based facilities in Paris (France), following a recent inspection by the French National Agency for the Safety of Medicine and Health Products (ANSM). PathoQuest is the first French CRO to offer GMP grade NGS-based testing services to assess the quality control of Human Medicinal Products and Human Investigational Medicinal Products.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211124005881/en/
This GMP certification acknowledges PathoQuest's testing activities meet the established high-quality control standards required by the biopharmaceutical industry. Biotech and biopharma companies may now transition from early-stage projects to more advanced clinical phases and commercial batch release using the power and precision of the NGS technology. PathoQuest today offers viral safety testing services and genetic characterization of biologics.
"Obtaining the GMP certification confirms that our quality management system meets the requirements and is at the expected level by the health authorities,” stated Violaine Mélen, PharmD, PathoQuest’s Chief Quality Assurance & Regulatory Affairs Officer and Qualified Person. The GMP certification for our biosafety testing services completes our GLP certificate obtained in January 2020 and the Pharmaceutical Establishment status achieved in September 2020. Offering GMP-grade genomic testing services is our pledge of quality to the biopharmaceutical industry, the health authorities and for the safety of the patient.
“Gaining this GMP certification is a major milestone in the implementation of PathoQuest’s growth strategy and strengthens our leadership in the quality control testing of biologics,” commented Jean-Francois Brepson, PathoQuest’s CEO . "By offering these testing services we will enable our clients to entrust their vaccine, cell and gene therapy, and other innovative therapies projects to PathoQuest, from early preclinical phases to commercial supply. We believe this represents a tremendous advantage for biopharmaceutical companies when they evaluate contract manufacturing alternatives that are faster, safer and 3R-compliant at a Good Manufacturing Practice grade. Those assets make PathoQuest the ideal partner.”
PathoQuest’s GMP certificate is available for our clients to download from our website along with the company’s current GLP certificate and the notice of achieving Pharmaceutical Establishment status.
About PathoQuest
PathoQuest offers biopharmaceutical companies a game-changing genomic approach at R&D, GLP and GMP grades to ensuring the biosafety of biologics like cell and gene therapy products, vaccines, and recombinant drugs. It enables a reduction in the time to market for these innovative treatments. PathoQuest’s technology combines an NGS platform with proprietary sample preparation processes followed by an automated analysis pipeline using the company’s proprietary pathogen genome sequences databases. PathoQuest entered into a strategic partnership with Charles River Laboratory (Boston, USA) in 2018.
For more information, visit www.pathoquest.com or contact us at welcome@pathoquest.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20211124005881/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Advances Its Carbon Minimal Inhaler Journey as European Submissions for Its Single Inhaler Triple Therapy (SITT) and ICS/LABA Combination Next-Generation Propellant pMDIs Are Validated3.9.2026 11:00:00 CEST | Press release
Key Highlights Regulatory submissions for next-generation propellant pMDIs (pressurized metered-dose inhalers) across Chiesi’s Single Inhaler Triple Therapy (SITT; or ICS/LABA/LAMA) and fixed double ICS/LABA combination (inhaled corticosteroid with a long-acting bronchodilator) range have been validated by Regulatory Agencies in Europe. Transition to HFA‑152a, a next‑generation propellant classified as non‑PFAS* and with low global warming potential (GWP),aimsto reduce the carbon footprint of Chiesi’s pMDIs by up to 90% compared to current ones.1-3 Designed for a seamless transition for patients and HCPs, maintaining established efficacy, safety and usability and supporting continuity of care.4-8 The validation supports Chiesi’s ambition to reach Net Zero† across its full value chain by 20359, following MHRA approval of Chiesi’s beclometasone pMDIs formulated with HFA-152a. Chiesi Group, an international research-focused biopharmaceutical company and certified B Corp, today announces a
Belkin præsenterer nye løsninger til at strømforsyne, lokalisere og personalisere hverdagens teknologi3.9.2026 10:00:00 CEST | Pressemeddelelse
Belkin International kan findes på IFA-messen i udstillingshal 3.2, stand nr. 117 Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag en ny kollektion af tilsluttet tilbehør, enhedsbeskyttelse og livsstilsløsninger, der er designet til at hjælpe forbrugerne med at holde styr på og personalisere de enheder, de er afhængige af. Den nye portefølje omfatter SureFind-kollektionen, BoostCharge Slim Magnetic Ring Stand, UltraCharge Smart Display-powerbanks og nye farvevarianter af Belkins populære BoostCharge Compact USB-C-oplader 30 W. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903932800/da/ Product lineup showcasing Belkin's newest mobile power accessories De nye produkter bygger på idéen om, at teknologi skal passe problemfrit ind i en moderne l
Quectel Expands RG660Qx 5G Module Capabilities for Future Railway Mobile Communication System Evaluation and Railway Applications3.9.2026 10:00:00 CEST | Press release
High-performance Sub-6GHz 5G module platform with support for FRMCS-related frequency bands enables early evaluation through a dedicated development environment. Quectel Wireless Solutions, a global IoT solutions provider, today announced an LGA version of its RG660Qx 5G module series, a high performance, Sub-6GHz 5G module platform that includes support for the Future Railway Mobile Communication System (FRMCS). Used with a dedicated evaluation environment comprising an adaptor board and EVB Kit, the RG660Qx enables equipment manufacturers and railway technology developers to conduct early Future Railway Mobile Communication System (FRMCS) evaluation and testing, supporting development ahead of the transition from GSM-R. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260903961434/en/ Quectel expands RG660Qx 5G module capabilities for Future Railway Mobile Communication System evaluation and railway applications The Future R
Belkin introducerer fremtidens bærbare strømforsyning med nye UltraCharge Pro Power Banks med halvfaste celler3.9.2026 10:00:00 CEST | Pressemeddelelse
Den næste generation af bærbar strømforsyning præsenteres for første gang på IFA 2026 og fremviser avanceret BoostSolid Cell-teknologi og ultraslanke design Belkin, der i mere end 40 år har været globalt førende inden for forbrugerelektronik, annoncerede i dag nye bærbare opladningsløsninger baseret på halvfast celleteknologi. Den nye UltraCharge Pro med BoostSolid Cell-serie er blandt Belkins første produkter med halvfast celleteknologi, et batteri af næste generation, der leverer forbedret holdbarhed, slankt design og længere batteritid – alt sammen uden at gå på kompromis med ydeevnen. De nyligt annoncerede produkter bliver præsenteret på IFA 2026, hvor Belkin udstiller på IFA-messen i hal 3.2, stand nr. 117. Der er multimedier i denne pressemeddelelse. Se hele meddelelsen her: https://www.businesswire.com/news/home/20260903417354/da/ Product image showcasing the first two Belkin power banks launched with BoostSolid technology Batteriteknologi af næste generation til længerevarende
I’m green™ bio-based Helps Deterra® Win Multiple Industry Awards for Pharmaceutical Packaging3.9.2026 10:00:00 CEST | Press release
The Deterra® Drug Disposal Pouch, which is made with 50% or more I'm green™ bio-based polymer, has gained Accredo Packaging a number of leading packing industry awards. Developed by Verde, the patented drug disposal technology is designed to deactivate unused medications, preventing drug diversion and mitigating the risk of pharmaceuticals leaching into groundwater and waterways. The partial use of I’m green™ bio-based polymer derived from renewable sugarcane, reduces the carbon footprint of the packaging material compared to equivalent fossil-based polyethylene, all whilst maintaining the technical performance required for pharmaceutical disposal applications. Material Innovation and Application The Deterra® pouch required a material that could meet strict technical specifications without relying entirely on traditional, fossil-based plastics. By utilizing I’m green™ bio‑based polyethylene, the packaging has a reduced carbon footprint whilst maintaining the performance of conventional
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom